List of Excipients in Branded Drug RISPERDAL CONSTA

Risperdal Consta Excipient Strategy and Commercial Opportunities

Last updated: September 7, 2026

Risperdal Consta is a long-acting intramuscular risperidone product whose commercial value depends more on microsphere engineering, reconstitution performance, manufacturing control, and injection usability than on the active ingredient alone. The formulation uses risperidone encapsulated in biodegradable poly(lactide-co-glycolide), or PLGA, microspheres. The accompanying diluent contains polysorbate 20, sodium carboxymethylcellulose, phosphate buffer, citric acid, sodium chloride, and water for injection.[1]

The main commercial opportunities are generic or follow-on long-acting injectable development, improved reconstitution systems, alternative biodegradable polymers, reduced injection burden, manufacturing technology, and excipient supply. Risperdal Consta is a chemical drug, not a biologic, so biosimilar regulation does not apply. Its regulatory challenge is the development of a complex injectable suspension with comparable drug release and clinical performance.

What excipients are used in Risperdal Consta?

Risperdal Consta uses different excipient systems in the microsphere phase and the supplied diluent.

Product component	Function	Reported material
Risperidone microspheres	Drug depot and controlled-release matrix	PLGA polymer containing risperidone
Microsphere polymer	Biodegradable drug-release carrier	Poly(DL-lactide-co-glycolide), commonly described as a 75:25 lactide:glycolide polymer
Diluent	Reconstitutes microspheres before injection	Water for injection
Surfactant	Improves wetting and dispersion	Polysorbate 20
Suspending agent	Controls settling and supports redispersion	Sodium carboxymethylcellulose
Buffer components	Controls pH	Disodium phosphate dihydrate and citric acid
Tonicity agent	Adjusts osmolality	Sodium chloride

The FDA labeling identifies the product as a powder for suspension for intramuscular injection supplied with a dedicated diluent and reconstitution device.[1] The excipients are not interchangeable functional components. Each influences particle wetting, suspension stability, needle delivery, depot formation, and the release profile.

Why PLGA is commercially important

PLGA controls risperidone release through polymer hydration, erosion, and diffusion. Polymer molecular weight, lactide-to-glycolide ratio, end-group chemistry, particle size, porosity, drug loading, residual solvent, and manufacturing temperature can change the release curve.

For a follow-on product, matching the nominal amount of risperidone is insufficient. The developer must control:

• Initial drug release after injection
• Duration and shape of the release curve
• Microsphere size distribution
• Surface morphology and porosity
• Polymer degradation profile
• Residual solvent levels
• Suspension uniformity after reconstitution
• Needle force and syringeability
• Sedimentation and redispersion time
• Compatibility with the injection device

These attributes create a higher technical barrier than an immediate-release risperidone tablet.

What role does the Risperdal Consta diluent play?

The diluent is part of the product’s performance system, not merely a vehicle. Sodium carboxymethylcellulose increases viscosity and helps keep the microspheres suspended. Polysorbate 20 improves wetting and reduces particle aggregation. The phosphate-citrate system controls pH, while sodium chloride supports isotonicity.

A substitute excipient can create several development problems:

1. A surfactant change can alter particle wetting and aggregation.
2. A viscosity change can affect syringeability and injection force.
3. A pH change can influence polymer hydrolysis and risperidone stability.
4. A tonicity change can affect local tolerability.
5. A preservative, if introduced, can create new compatibility and regulatory issues.
6. A different buffer can modify the release rate after reconstitution.

The diluent also affects the practical administration window. A product that settles quickly or requires prolonged shaking increases administration time and creates dose-uniformity risk in clinical practice.

What excipient strategies can support a generic Risperdal Consta product?

A generic strategy should begin with a Q1/Q2 assessment of the reference product’s inactive ingredients, followed by a target product profile for critical quality attributes. The most defensible approach is usually to preserve the established excipient architecture unless the developer has a strong reason to change it.

Strategy 1: Match the reference excipient system

Using the same functional classes of excipients reduces formulation risk. The developer can pursue differentiation through manufacturing efficiency, device packaging, supply reliability, or cost.

This approach does not eliminate regulatory risk. Even when the excipient list is similar, differences in polymer grade, molecular-weight distribution, particle morphology, and release kinetics can make the product pharmaceutically non-equivalent.

Strategy 2: Improve suspension and reconstitution performance

A follow-on product could target:

• Faster wetting
• Shorter shaking time
• Lower sedimentation rate
• Easier redispersion
• Lower injection force
• Reduced needle clogging
• Longer post-reconstitution stability
• Lower residual volume in the vial or syringe

These improvements may support a differentiated 505(b)(2) product or device strategy, depending on the extent of formulation and clinical changes. They are less likely to create meaningful differentiation if they do not improve administration, adherence, storage, or total treatment cost.

Strategy 3: Replace the diluent with a ready-to-use suspension

Risperdal Consta requires reconstitution before administration. A ready-to-use liquid suspension could remove a preparation step and reduce administration errors. The technical barriers include:

• Long-term physical stability
• Prevention of particle aggregation
• Control of sedimentation
• Maintenance of injectability
• Microbial control
• Container closure compatibility
• Stability under shipping stress
• Preservation of the original release profile

A ready-to-use formulation may require a new regulatory strategy because the formulation, packaging, and administration process would differ from the reference product.

Strategy 4: Use a different biodegradable polymer

Alternative PLGA grades or related biodegradable polymers could support a differentiated release profile. Potential variables include:

• Lactide:glycolide ratio
• Polymer molecular weight
• End-group chemistry
• Polymer concentration
• Drug-to-polymer ratio
• Microsphere production process

This strategy carries the greatest comparability risk. A polymer change can produce a different initial release, duration, depot structure, or local tissue response. It is commercially attractive only if the product delivers a measurable benefit, such as a longer dosing interval or more predictable exposure.

What manufacturing IP barriers affect risperidone microspheres?

The strongest barriers are likely to reside in process know-how rather than in basic excipient selection. Relevant manufacturing technologies include:

• Emulsion-solvent evaporation
• Spray drying
• Microfluidic particle production
• Controlled polymer precipitation
• Particle-size classification
• Aseptic filling of microspheres
• Residual-solvent removal
• Sterile filtration of process streams where feasible
• In-process control of drug loading and particle morphology

The critical process parameters must be linked to critical quality attributes. A manufacturer with a robust scale-up history may have an advantage even when composition patents have expired.

Manufacturing know-how can also protect:

• Stable microsphere morphology
• Reproducible drug loading
• Low batch-to-batch release variability
• High recovery of polymer and active ingredient
• Lower solvent consumption
• Reduced sterile processing losses

These advantages may not appear in an Orange Book patent listing but can affect cost, supply reliability, and regulatory execution.

When does Risperdal Consta lose exclusivity?

Risperdal Consta was approved by the FDA in 2003 under NDA 021346.[1] Its regulatory exclusivity and principal product patents are no longer the primary commercial barriers. FDA approval records identify generic risperidone extended-release injectable suspension products, including Teva’s generic version, demonstrating that the market is open to abbreviated applications.[2]

The product’s practical exclusivity profile is summarized below.

Issue	Commercial position
New chemical entity exclusivity	Expired
Original NDA approval	2003
Biosimilar pathway	Not applicable
Generic pathway	Available for risperidone extended-release injectable suspension
Primary remaining barriers	Complex formulation, manufacturing, device, clinical comparability, and supply
Key reference product	Risperdal Consta, Janssen Pharmaceuticals

Exact patent term analysis should distinguish composition, formulation, manufacturing, and device claims. Expiration of an active-ingredient patent does not automatically remove all process or device restrictions. The FDA Orange Book remains the controlling source for patents listed against the NDA.[3]

What is the Orange Book status of Risperdal Consta?

Risperdal Consta is listed under NDA 021346 in FDA drug-reference materials. The Orange Book identifies approved products, therapeutic-equivalence information, and patent or exclusivity data where applicable.[3]

For commercial planning, the relevant distinction is between:

• Patents listed against the reference product
• Expired patents that no longer block launch
• Unlisted manufacturing know-how
• Device or packaging rights
• Third-party polymer and excipient supply agreements
• Product-liability and sterile manufacturing risks

A generic applicant must evaluate Paragraph IV exposure for any unexpired listed patent. The existence of a Paragraph IV certification can trigger Hatch-Waxman litigation and a potential 30-month stay, subject to the statutory requirements. Public FDA approval of a generic risperidone microsphere product indicates that the core reference-product barrier has been overcome for at least one applicant.[2]

Which companies are challenging or competing with Risperdal Consta?

The principal competitive categories are generic risperidone microspheres, alternative long-acting antipsychotics, and emerging long-acting formulations.

Competitor category	Examples	Competitive effect
Generic risperidone LAI	Teva generic risperidone extended-release injectable suspension	Direct price competition
Paliperidone palmitate	Invega Sustenna, Invega Trinza, Invega Hafyera	Longer dosing intervals and established LAI franchise
Aripiprazole LAI	Abilify Maintena, Aristada	Alternative mechanism and dosing schedules
Olanzapine pamoate	Zyprexa Relprevv	Alternative atypical antipsychotic with administration restrictions
Future risperidone depot products	New PLGA, in situ depot, or ready-to-use systems	Potential dosing and usability differentiation

Risperidone and paliperidone are pharmacologically related, but their commercial positioning differs. Paliperidone products have extended dosing intervals that can reduce administration frequency. A new risperidone formulation would need to compete on interval, tolerability, convenience, cost, or supply.

Are biosimilars a risk for Risperdal Consta?

No. Risperidone is a synthetic small-molecule active ingredient. Risperdal Consta is regulated as a drug product, not as a biologic subject to the biosimilar pathway under the Public Health Service Act.

The relevant competitors are ANDA products and, potentially, 505(b)(2) products. Because Risperdal Consta is a complex microsphere injectable, generic development may require extensive comparative characterization and, depending on FDA requirements, clinical or pharmacokinetic evidence beyond the normal expectations for a simple tablet.

What Paragraph IV and litigation risks apply?

A prospective applicant should analyze four legal layers:

1. Orange Book-listed patents for the NDA.
2. Unlisted patents covering manufacturing, devices, or packaging.
3. Trade-secret risk in the reference product’s manufacturing process.
4. Contractual restrictions involving polymer, device, or sterile manufacturing suppliers.

Paragraph IV litigation is most relevant to any unexpired listed patent. A generic applicant can challenge patent validity, enforceability, or infringement through an ANDA certification. A 30-month stay may delay approval, but it does not guarantee that the patent survives litigation.

Settlement agreements may affect launch timing, authorized generic exposure, or royalty economics. No settlement term should be inferred from FDA approval alone. Commercial diligence requires review of court records, FDA listing data, and applicant-specific litigation filings.

What commercial opportunities exist in Risperdal Consta excipients?

Excipient supply

Suppliers can target pharmaceutical-grade PLGA, polysorbate 20, sodium carboxymethylcellulose, and specialty diluent systems. The highest-value opportunity is not commodity volume alone. It is consistent control of:

• Polymer molecular weight
• Lactide:glycolide ratio
• Residual monomer
• Endotoxin
• Bioburden
• Particle and solution cleanliness
• Lot-to-lot release behavior

A qualified dual-source polymer supply can have value for generic manufacturers seeking launch reliability.

Contract development and manufacturing

CDMOs with sterile microsphere capability can capture demand from companies lacking:

• Scale-up equipment
• Aseptic microsphere processing
• Release-testing infrastructure
• Injectable suspension filling
• Regulatory comparability expertise

The most defensible CDMO position combines formulation development with validated commercial manufacturing.

Device and packaging

The original product’s reconstitution process creates opportunities for:

• Dual-chamber syringes
• Integrated transfer devices
• Preassembled reconstitution systems
• Low-dead-volume syringes
• Needle-protection systems
• Reduced-shaking packaging
• Administration kits optimized for outpatient clinics

Device differentiation may support a 505(b)(2) product, but device changes can create new human-factors, combination-product, and compatibility requirements.

Lifecycle extension

A reformulated risperidone depot could target:

• Monthly dosing with simpler preparation
• Six-week or longer dosing
• Ready-to-use administration
• Lower injection volume
• Lower injection-site burden
• Improved storage conditions
• Reduced need for oral supplementation

The commercial value increases if a formulation can show better persistence, lower missed-dose risk, or lower total administration cost.

How strong is the Risperdal Consta patent estate?

The estate is commercially weaker than it was during the original launch period because the active ingredient is long established and generic competition exists. The remaining strategic value lies in formulation-process knowledge, device integration, polymer sourcing, and execution speed.

Estate component	Relative commercial strength
Risperidone molecule	Low; mature generic active ingredient
Basic PLGA depot concept	Low to moderate; broad concepts are vulnerable to expiration or invalidity
Specific microsphere process	Moderate; process reproducibility can create practical barriers
Reconstitution system	Moderate; depends on active device and formulation claims
Ready-to-use or extended-interval formulation	Potentially high if supported by valid claims and clinical differentiation
Manufacturing trade secrets	Moderate to high in practice, but difficult to enforce against independent development
Excipient supply position	Moderate when tied to validated polymer grades and regulatory history

Patent value should be separated from technical value. An expired patent may still describe the reference product’s design, while the economic barrier has shifted to manufacturing capability and regulatory execution.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible.

Low-price generic launch

A manufacturer uses a reference-like excipient system and competes mainly on price. This approach can gain share but may face margin pressure, limited differentiation, and supply-chain vulnerability.

Premium generic with administration improvements

The product retains the established PLGA depot but improves reconstitution, packaging, or injection performance. The applicant may obtain better institutional uptake if the improvement reduces staff time or administration errors.

Reformulated follow-on product

A new polymer, ready-to-use suspension, or longer-interval product seeks differentiated pricing. This route has greater development cost and regulatory risk but may avoid direct commodity competition.

Key Takeaways

• Risperdal Consta uses risperidone-loaded PLGA microspheres and a diluent containing polysorbate 20, sodium carboxymethylcellulose, phosphate, citrate, sodium chloride, and water for injection.
• The core commercial barrier is microsphere performance, not the risperidone molecule.
• Polymer grade, particle size, drug loading, residual solvent, release kinetics, and reconstitution behavior are the central development variables.
• Biosimilar regulation does not apply. Generic and 505(b)(2) pathways are the relevant routes.
• Generic competition has entered the market, reducing the value of a simple copy strategy.
• Strongest opportunities include improved reconstitution, ready-to-use delivery, device integration, longer dosing intervals, validated PLGA supply, and sterile microsphere manufacturing.
• Manufacturing know-how may remain commercially important even when patent protection has expired.
• A successful follow-on product must demonstrate comparable depot performance or offer a measurable clinical, operational, or economic advantage.

FAQs

What is the main excipient in Risperdal Consta?

The principal structural excipient is PLGA, which forms the biodegradable microsphere matrix that controls risperidone release.

Does Risperdal Consta contain polysorbate 80?

The labeled diluent contains polysorbate 20, not polysorbate 80.[1]

Can Risperdal Consta be reformulated as a prefilled syringe?

Potentially, but a prefilled presentation would require proof of suspension stability, dose uniformity, syringe compatibility, injectability, container closure integrity, and an appropriate FDA regulatory pathway.

Is PLGA a patentable excipient strategy for risperidone?

PLGA itself is a mature polymer. Commercial protection is more likely to arise from a specific polymer grade, microsphere structure, manufacturing process, release profile, or combination with a delivery device than from PLGA as a generic material.

What is the largest commercial weakness of a Risperdal Consta generic?

The largest weakness is the cost and complexity of producing a sterile, reproducible long-acting microsphere injectable while competing against established long-acting antipsychotics with longer dosing intervals.

References

1. U.S. Food and Drug Administration. (2024). Risperdal Consta: Prescribing information, NDA 021346. Janssen Pharmaceuticals.

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: Risperidone for extended-release injectable suspension. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2022). Product-specific guidance for risperidone injectable suspension. Center for Drug Evaluation and Research.

5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.